EXFORGE HCT
LOE ApproachingNDAORALTABLET
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
6/8 — Strong
EXFORGE HCT by Novartis is 3 separate mechanisms involved in blood pressure regulation. Approved for hypertension, to lower blood pressure, hypertension to lower blood pressure. First approved in 2009.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXFORGE HCT is a fixed-dose oral combination tablet containing amlodipine (calcium channel blocker), valsartan (ARB), and hydrochlorothiazide (thiazide diuretic) approved in 2009. It treats hypertension by blocking angiotensin II receptors, reducing peripheral vascular resistance, and promoting sodium/water excretion. This triple-therapy approach addresses resistant hypertension in patients requiring multi-drug management.
$988KPart D
LOE ApproachingDeclining
Mature, declining portfolio asset with minimal team expansion; roles focused on lifecycle management and generic transition planning rather than growth initiatives.
Mechanism of Action
3 separate mechanisms involved in blood pressure regulation. Specifically, amlodipine blocks the contractile effects of calcium on cardiac and vascular smooth muscle cells; valsartan blocks the vasoconstriction and sodium retaining effects of angiotensin II on cardiac, vascular smooth muscle,…
Worked on EXFORGE HCT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.